OBJECTIVE: To clarify whether maternal @entity23109 positivity may add risk for adverse neonatal outcomes and even affect @entity1 's growth. METHODS: The perinatal data and neonatal outcomes in 380 @entity23109 -positive and 428 @entity23109 -negative @entity1 delivered during 2002-2004 were investigated. Furthermore, 271 (71.3%) @entity1 of @entity23109 -positive and 297 (69.4%) of @entity23109 -negative mothers were followed at ages of 5-7 years. @entity1 's growth including weight, height, and health conditions were evaluated. RESULTS: The prevalence of preterm birth was relatively higher in @entity23109 -positive group (2.9% versus 1.4%), but it failed to reach statistical significance (p   =   0.140). There was no difference in other neonatal outcomes including stillbirth (0.5% versus 0.2%), neonatal death (0.5% versus 0.5%) and congenital malformation (0.8% versus 1.4%). Logistic regression analyses demonstrated maternal @entity23109 positivity had no adverse influence on neonatal outcomes. Abnormal health conditions, other than adverse neonatal outcomes, was identified in one @entity1 (0.3%) of @entity23109 -positive mother and four @entity1 (0.9%) of @entity23109 -negative mothers at follow-up (p   =   0.444). No maternal death occurred in @entity23109 -positive or -negative mothers. CONCLUSIONS: Maternal @entity23109 carrier status does not add risk for adverse neonatal outcomes or @entity1 's growth; therefore, heightening surveillance for adverse neonatal complications in @entity97 -infected pregnant @entity1 may be unnecessary.

Minimal adverse influence of maternal hepatitis B carrier status on perinatal outcomes and XXXX 's growth.

@entity1 :: ('9606', 'Species') :: ['Child', 'women', 'children', 'child'] @entity97 :: ('10407', 'Species') :: ['HBV'] @entity23109 :: ('MESH:D006514', 'Chemical') :: ['HBsAg']
@entity1 :: (9606,Species) :: ['child']
